vs

Side-by-side financial comparison of AvePoint, Inc. (AVPT) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $114.7M, roughly 1.7× AvePoint, Inc.). AvePoint, Inc. runs the higher net margin — 13.6% vs 6.7%, a 6.9% gap on every dollar of revenue. On growth, AvePoint, Inc. posted the faster year-over-year revenue change (28.6% vs 13.6%). AvePoint, Inc. produced more free cash flow last quarter ($29.0M vs $17.6M). Over the past eight quarters, AvePoint, Inc.'s revenue compounded faster (24.0% CAGR vs 14.4%).

AvePoint is a public company headquartered in Jersey City, New Jersey, United States. It develops software products intended to add features or security to other major platforms, like Microsoft 365, Google, or Salesforce. AvePoint was founded in 2001 and went public on NASDAQ in 2020.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

AVPT vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.7× larger
RGEN
$197.9M
$114.7M
AVPT
Growing faster (revenue YoY)
AVPT
AVPT
+15.0% gap
AVPT
28.6%
13.6%
RGEN
Higher net margin
AVPT
AVPT
6.9% more per $
AVPT
13.6%
6.7%
RGEN
More free cash flow
AVPT
AVPT
$11.4M more FCF
AVPT
$29.0M
$17.6M
RGEN
Faster 2-yr revenue CAGR
AVPT
AVPT
Annualised
AVPT
24.0%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVPT
AVPT
RGEN
RGEN
Revenue
$114.7M
$197.9M
Net Profit
$15.6M
$13.3M
Gross Margin
73.6%
52.5%
Operating Margin
12.7%
9.0%
Net Margin
13.6%
6.7%
Revenue YoY
28.6%
13.6%
Net Profit YoY
191.1%
143.9%
EPS (diluted)
$0.06
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVPT
AVPT
RGEN
RGEN
Q4 25
$114.7M
$197.9M
Q3 25
$109.7M
$188.8M
Q2 25
$102.0M
$182.4M
Q1 25
$93.1M
$169.2M
Q4 24
$89.2M
$174.1M
Q3 24
$88.8M
$154.9M
Q2 24
$78.0M
$154.1M
Q1 24
$74.5M
$151.3M
Net Profit
AVPT
AVPT
RGEN
RGEN
Q4 25
$15.6M
$13.3M
Q3 25
$13.0M
$14.9M
Q2 25
$2.9M
$14.9M
Q1 25
$3.6M
$5.8M
Q4 24
$-17.2M
$-30.3M
Q3 24
$2.6M
$-654.0K
Q2 24
$-12.9M
$3.3M
Q1 24
$-2.0M
$2.1M
Gross Margin
AVPT
AVPT
RGEN
RGEN
Q4 25
73.6%
52.5%
Q3 25
74.4%
53.2%
Q2 25
74.0%
50.0%
Q1 25
74.3%
53.6%
Q4 24
75.4%
26.1%
Q3 24
76.1%
50.0%
Q2 24
75.7%
49.8%
Q1 24
72.6%
49.5%
Operating Margin
AVPT
AVPT
RGEN
RGEN
Q4 25
12.7%
9.0%
Q3 25
7.4%
8.9%
Q2 25
7.0%
7.6%
Q1 25
3.5%
3.9%
Q4 24
5.4%
-17.7%
Q3 24
8.6%
-5.1%
Q2 24
-2.7%
1.0%
Q1 24
-4.3%
1.3%
Net Margin
AVPT
AVPT
RGEN
RGEN
Q4 25
13.6%
6.7%
Q3 25
11.9%
7.9%
Q2 25
2.8%
8.2%
Q1 25
3.8%
3.4%
Q4 24
-19.3%
-17.4%
Q3 24
3.0%
-0.4%
Q2 24
-16.6%
2.2%
Q1 24
-2.6%
1.4%
EPS (diluted)
AVPT
AVPT
RGEN
RGEN
Q4 25
$0.06
$0.24
Q3 25
$0.06
$0.26
Q2 25
$0.01
$0.26
Q1 25
$0.02
$0.10
Q4 24
$-0.09
$-0.55
Q3 24
$0.01
$-0.01
Q2 24
$-0.07
$0.06
Q1 24
$-0.01
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVPT
AVPT
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$481.1M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$478.7M
$2.1B
Total Assets
$789.2M
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVPT
AVPT
RGEN
RGEN
Q4 25
$481.1M
$767.6M
Q3 25
$471.6M
$748.7M
Q2 25
$430.1M
$708.9M
Q1 25
$351.8M
$697.2M
Q4 24
$290.9M
$757.4M
Q3 24
$250.0M
$784.0M
Q2 24
$230.8M
$809.1M
Q1 24
$219.3M
$780.6M
Total Debt
AVPT
AVPT
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AVPT
AVPT
RGEN
RGEN
Q4 25
$478.7M
$2.1B
Q3 25
$466.8M
$2.1B
Q2 25
$443.1M
$2.1B
Q1 25
$361.5M
$2.0B
Q4 24
$270.9M
$2.0B
Q3 24
$215.7M
$2.0B
Q2 24
$207.4M
$2.0B
Q1 24
$212.7M
$2.0B
Total Assets
AVPT
AVPT
RGEN
RGEN
Q4 25
$789.2M
$2.9B
Q3 25
$743.5M
$2.9B
Q2 25
$700.1M
$2.9B
Q1 25
$598.8M
$2.9B
Q4 24
$519.1M
$2.8B
Q3 24
$463.0M
$2.8B
Q2 24
$427.3M
$2.9B
Q1 24
$413.8M
$2.8B
Debt / Equity
AVPT
AVPT
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVPT
AVPT
RGEN
RGEN
Operating Cash FlowLast quarter
$29.7M
$25.7M
Free Cash FlowOCF − Capex
$29.0M
$17.6M
FCF MarginFCF / Revenue
25.3%
8.9%
Capex IntensityCapex / Revenue
0.6%
4.1%
Cash ConversionOCF / Net Profit
1.90×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$81.6M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVPT
AVPT
RGEN
RGEN
Q4 25
$29.7M
$25.7M
Q3 25
$34.8M
$48.1M
Q2 25
$20.3M
$28.6M
Q1 25
$495.0K
$15.0M
Q4 24
$32.8M
$39.2M
Q3 24
$32.2M
$49.3M
Q2 24
$16.2M
$42.2M
Q1 24
$7.8M
$44.7M
Free Cash Flow
AVPT
AVPT
RGEN
RGEN
Q4 25
$29.0M
$17.6M
Q3 25
$34.3M
$43.4M
Q2 25
$19.3M
$21.5M
Q1 25
$-1.0M
$11.4M
Q4 24
$32.0M
$33.6M
Q3 24
$30.8M
$42.3M
Q2 24
$15.8M
$37.4M
Q1 24
$7.3M
$36.4M
FCF Margin
AVPT
AVPT
RGEN
RGEN
Q4 25
25.3%
8.9%
Q3 25
31.3%
23.0%
Q2 25
18.9%
11.8%
Q1 25
-1.1%
6.8%
Q4 24
35.9%
19.3%
Q3 24
34.7%
27.3%
Q2 24
20.2%
24.3%
Q1 24
9.7%
24.0%
Capex Intensity
AVPT
AVPT
RGEN
RGEN
Q4 25
0.6%
4.1%
Q3 25
0.5%
2.5%
Q2 25
0.9%
3.9%
Q1 25
1.6%
2.1%
Q4 24
0.8%
3.2%
Q3 24
1.6%
4.5%
Q2 24
0.5%
3.1%
Q1 24
0.7%
5.5%
Cash Conversion
AVPT
AVPT
RGEN
RGEN
Q4 25
1.90×
1.93×
Q3 25
2.68×
3.23×
Q2 25
7.01×
1.92×
Q1 25
0.14×
2.57×
Q4 24
Q3 24
12.30×
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVPT
AVPT

SAAS$88.9M78%
Services$14.7M13%
Termed License And Support$10.1M9%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons